Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

November 23, 2022

Study Completion Date

December 16, 2022

Conditions
Opioid Use Disorder
Interventions
DEVICE

PEAR-002B

PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder

DEVICE

reSET-O

reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.

Trial Locations (1)

08009

Hassman Research Institute, LLC, Berlin

Sponsors
All Listed Sponsors
collaborator

Kaiser Foundation Research Institute

OTHER

collaborator

Whitman-Walker Institute, Inc.

OTHER_GOV

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Hassman Research Institute, LLC

UNKNOWN

lead

Pear Therapeutics, Inc.

INDUSTRY